BroadOak Capital Partners and RCT Invest in Biolog, Inc.
May 12, 2022
BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.
- Buyers
- BroadOak Capital Partners, Research Corporation Technologies (RCT)
- Targets
- Biolog, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
BroadOak Capital Partners Makes $2.0M Growth Investment in KromaTiD
April 28, 2021
Biotechnology
BroadOak Capital Partners provided $2.0 million of growth capital to KromaTiD to accelerate commercialization, support product development (including dGH In-Site and dGH SCREEN) and expand capacity to meet rising demand. KromaTiD, a Longmont, Colorado-based provider of single-cell genomic structural analysis for gene editing and gene therapy applications, will use the funding to grow its services and product offerings to biopharma and research customers.
-
BroadOak Capital Partners Invests Growth Capital in PhenoVista Biosciences
January 18, 2022
Biotechnology
PhenoVista Biosciences, a San Diego–based provider of high-content, imaging-based phenotypic assay services, raised growth capital from BroadOak Capital Partners. The funding will be used to accelerate development of complex biological models (e.g., blood–brain barrier, neurodegenerative disease platforms) and expand PhenoVista's assay and data-analysis capabilities.
-
Research Corporation Technologies Acquires Translational Drug Development (TD2)
June 4, 2020
Healthcare Services
Research Corporation Technologies, Inc. (RCT) has acquired Translational Drug Development (TD2) and provided growth capital to expand TD2's precision oncology drug development services. The transaction will scale TD2's translational preclinical, regulatory and clinical trial capabilities to better serve biotechnology and pharmaceutical clients.
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories
January 8, 2019
Healthcare Services
Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.
-
RC Capital Acquires Majority Stake in Cognitive Research Corporation
October 25, 2022
Healthcare Services
RC Capital completed a growth recapitalization investment to acquire a majority stake in Cognitive Research Corporation (CRC), a St. Petersburg, Florida-based contract research organization specializing in CNS clinical development and cognitive assessment technology. The investment will fund business development, service expansion and global growth while founders and management retain a significant ownership position; financial terms were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.